Here's why I added Resmed shares to my portfolio last week

Fear is consuming the Resmed share price. I've decided to take action while the market is panicking.

| More on:
A man sleeps in a bed with white sheets while holding a teddy bear and a smile on his face.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

In less than two months, Resmed Inc (ASX: RMD) shares have cascaded 35.7% to their lowest price since March 2020.

The violent hit to the medical device company comes amid mounting fears of market disruption caused by glucagon-like peptide 1 (GLP-1) drugs.

Going against the grain, I decided to buy Resmed shares last week. In this article, I'll explain why I think the market is being irrational and how Resmed could still succeed in this evolving landscape.

Shoot first, ask questions later

Known more commonly by their label names, such as Wegovy and Mounjaro, weight-loss medications are creating a ruckus in the healthcare industry. The fear is that GLP-1s could uproot existing indirect treatments due to the prevalent link between an array of health issues and obesity.

It's a classic example of root cause analysis: addressing the source of the problem rather than trying to treat the symptoms.

Resmed is a big player in treating obstructive sleep apnea (OSA) — a sleep disorder believed to affect 20% of the global population. It is commonly cited that obesity is considered one of the main risk factors for sleep apnea, with estimates indicating roughly 70% of OSA sufferers are obese.

Investors are worried that these new medications could usurp Resmed by solving the underlying cause of the disorder it treats, hurting Resmed shares. While the jury is still out on the substantive evidence, it appears shareholders are not waiting around to find out.

Three reasons why I think GLP-1s won't eat Resmed's lunch

I want to provide three clear-cut points for why I added Resmed to my portfolio.

  1. Early evidence for reduced sleep apnea from GLP-1 use is combined with exercise and a restrictive diet. This may suggest that sleep apnea issues could persist without lifestyle changes.
  2. If GLP-1s do disrupt the OSA industry, the market opportunity remains significant. An estimated ~485 million people with sleep apnea are not exposed to obesity — Resmed currently serves around 160 million.
  3. Weight-loss medications and continuous positive airway pressure machines (CPAP) — the devices Resmed sells — could be complementary.

Homing in on that last point. The real winners from this are the people who suffer from sleep apnea. It may give people more choice. Studies show that some people don't stick with CPAP machines… likewise, others don't gel with these new medications.

I think investors are forgetting that different solutions can co-exist in large markets.

Pulling the trigger on Resmed shares

I have long admired Resmed as a company. The ability to constantly innovate on its devices, expand its market share, and maintain commendable margins.

However, during my time as an investor, the Resmed shares price has usually traded on a price-to-earnings (P/E) ratio of between 30 and 50 times. I couldn't stomach the premium price. A mistake in hindsight.

The market's recent irrationality, in my opinion, has given me a second chance. Now, Resmed trades at 24 times earnings.

Still conscious of the risks, I have added a modest position with the intention to add more in the future. Right now, Resmed shares make up 2.7% of my personal portfolio.

Motley Fool contributor Mitchell Lawler has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Opinions

Smiling man at the wheel of a car.
Opinions

2 ASX auto stocks to buy — and 1 to sell: experts

Analysts have shared fresh insights into 3 ASX auto shares -- and not all of them are in the buy…

Read more »

A male investor sits at his desk pondering at his laptop screen with a piece of paper in his hand.
Opinions

ASX retail share whose 'fundamentals have deteriorated significantly': expert

Christopher Watt from Bell Potter explains his views on this former market darling.

Read more »

A young woman looks at something on her laptop, wondering what will come next.
Opinions

3 soaring ASX 200 large-cap shares that are now overvalued: experts

Two experts say this trio of ASX 200 large-caps have overshot and it's time to take some profits.

Read more »

Man sitting in a plane seat works on his laptop.
Opinions

Expert reveals 2 ASX stocks to sell — and 1 is a recent IPO

Toby Grimm from Baker Young shares his insights.

Read more »

An analyst wearing a dark blue shirt and glasses sits at his computer with his chin resting on his hands as he looks at the CBA share price movement today
Opinions

Expert's verdict on 3 ASX 200 shares (2 have doubled in value and the other has lost 29%)

Two of these stocks were the best performers of their sectors in FY25. Should you buy, hold, or sell?

Read more »

A male investor sits at his desk pondering at his laptop screen with a piece of paper in his hand.
Opinions

Where I'd invest in ASX shares ahead of the likely RBA rate cut

These stocks look too good to miss.

Read more »

Person pretends to types on laptop drawn in sand.
Opinions

I sold one of my oldest ASX 200 shares last week. Here's why

Why would I sell one of my longest-held stocks?

Read more »

Broker analysing the share price.
Materials Shares

Buy, hold, or sell? Broker's verdict on 3 ASX 200 materials shares

Materials was one of four market sectors that weakened in overall value in FY25.

Read more »